Related Experiment Video
Updated: Jan 22, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
Jennifer Miles1, Yahsin White1
1Wellmont Cancer Institute-Johnson City, Johnson City, Tennessee.
Abstract:
The treatment of breast cancer has been revolutionized by the development of HER2-targeted treatments for patients who are HER2 positive. The HER2 protein is present at high levels in about 30% of breast cancer patients. These high levels are associated with a greater chance of metastasis, relapse, and decreased survival. The current standard of care for early-stage HER2-positive patients includes treatment with 1 year of trastuzumab therapy. Although trastuzumab has improved outcomes, there is still a 20% chance for tumor recurrence and a 16% chance of death. Neratinib was developed to give patients with early-stage HER2-positive breast cancer an option to increase the disease-free survival rate. The 5-year invasive disease-free survival rate was 90.2% (95% confidence interval = 88.3-91.8) in the neratinib group and 87.7% (95% confidence interval = 85.7-89.4) in the placebo group.
Related Concept Videos
Treatment Resistant Cancers
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Positive Regulator Molecules
Position and Displacement
Serial Position Effect

